We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





MeMed Highlights Pioneering Blood Test for Accurately Distinguishing Between Bacterial and Viral Infection

By LabMedica International staff writers
Posted on 26 Apr 2022
Print article
Image: MeMed BV blood test accurately distinguishes between bacterial and viral infection (Photo courtesy of MeMed)
Image: MeMed BV blood test accurately distinguishes between bacterial and viral infection (Photo courtesy of MeMed)

MeMed (Haifa, Israel) hosted an integrated symposium, oral presentation and poster spotlighting MeMed BV at the 32nd European Congress of Clinical Microbiology and Infectious Diseases Conference (ECCMID) in Lisbon, Portugal, April 23-26, 2022. Clinical key opinion leaders presented clinical use and performance data in scientific sessions, including an integrated symposium, oral abstract presentation and poster abstract on MeMed BV performance validation data.

MeMed BV is a pioneering blood test to help physicians with the seemingly simple clinical dilemma - does a patient have a bacterial or viral infection. The test harnesses the power of the body’s immune system and delivers results in just 15 minutes. MeMed BV measures and computationally integrates the levels of three immune system proteins: TRAIL, IP-10 and CRP. MeMed BV is the only test for distinguishing bacterial from viral infections that has been validated in multinational, double-blind and external clinical studies. The clinical studies demonstrating the diagnostic performance of MeMed BV encompassed thousands of patients and are published in high impact medical journals.

Unlike most conventional solutions that seek to detect bacteria or viruses, MeMed BV is an advanced host response test that uses the human immune system as the disease sensor. This approach offers unique advantages far beyond speed and accuracy: (i) It can diagnose cases when the infection site is not readily accessible or is unknown (e.g., pneumonia or fever without source) because immune markers circulate throughout the body; (ii) It can prevent false alarms due to detection of bacteria or viruses that are mere bystanders and are not causing the disease; (iii) It is robust to rapidly evolving pathogens. The MeMed BV test runs on MeMed Key, a cutting edge, compact immunoassay platform that is accurate and easy to use, making it possible to conduct highly sensitive, rapid, multiplexed protein measurements that previously could only be done on expensive central lab equipment.

Related Links:
MeMed 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Strep Pneumoniae Rapid Test
Strep Pneumoniae (6503 – 6573)
New
Cryptosporidium Infection Test
Crypto (Card) Rapid Test
New
Cytomegalovirus Assay
Alethia CMV

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: Lunit SCOPE HER2 is an AI-powered solution designed to detect HER2 expression profile (Photo courtesy of Lunit)

AI-Powered Pathology Solutions Accurately Predict Outcomes for HER2-Targeted Therapy in Metastatic CRC

A new study has highlighted how artificial intelligence (AI)-powered analysis of HER2 and the tumor microenvironment (TME) can improve patient stratification and predict clinical outcomes more effectively.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.